Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
They had it in last few years at both ASH and EHA.
is there supposed to be an update?
Chances are reasonable, but not in Aptose hands.
Decaf, what do you think the odds are that the drug will be successful? tia
From prospectus. Based on the safety and efficacy profile of tuspetinib, we believe that tuspetinib, if approved, can reach greater than $3 billion in annual sales by 2035 because we believe tuspetinib could (1) become the preferred kinase inhibitor for inclusion in triplet combination for front line AML patients with FLT3 mutations and for patients with wild type FLT3, (2) become the preferred kinase inhibitor for inclusion in doublet combination with venetoclax for second line R/R AML patients, (3) serve as an effective agent for maintenance therapy to prevent relapse in patients who achieved a CR through a stem cell transplant or through drug-based therapy, and 4) serve as an effective agent for the treatment of third line FLT3 mutated patients failed by prior therapy with other FLT3 inhibitors. In addition, we plan to test tuspetinib for efficacy and safety in patients with MDS, and, if found active and safe in this population, could support the overall market potential of tuspetinib at $3 billion sales annually.
Pre-ASH run? Tuspetinib will be presented at Post-ASH 2023 AML Highlights with discussions on selected AML abstracts from the 65th ASH Annual Meeting.
https://www.vjhemonc.com/feature/post-ash-2023-aml-highlights/
Actually, I am intrigued by other talk in Session 2: FLT3-Mutated Disease, entitled "The FLT3-like Gene Expression Signature Predicts Response to Quizartinib in Wild-Type FLT3 AML: Analysis of Pethema Quiwi". It looks like, the authors found a group of genes that predicts responsiveness of AML patients with FLT3 WT to FLT3 inhibitors. Quiz, like Tusp, works in FLT3 WT population. Interesting. Could be useful for Tusp as well.
Not a good situation, thanks
They said word "partner" many times and they are using ATM. Expect that any SP increase with good news will be immediately killed by ATM. With very low daily trading volume, it is inevitable.
Did you see anything new today Decaf?
Hi Tartia. You’ve been too quiet lately. Could you please share your thoughts on the latest released results? Much appreciated!
Would take that deal all day long
Thanks decaf! Looks like they’re quite a bit behind us.
Just an example of a good deal in AML announced today, "Bristol Myers buys Orum's blood cancer therapy in $180M deal. The parties entered into a definitive agreement under which Bristol Myers' (BMY) acquired Orum's ORM-6151 program for an upfront payment of $100M. Orum is also eligible to receive milestone payments as part of the deal. ORM-6151 is a first-in-class, anti-CD33 antibody-enabled GSPT1 degrader that has received the U.S. Food and Drug Administration's clearance for an early stage study for the treatment of patients with acute myeloid leukemia or high-risk myelodysplastic syndromes". And they don't have any clinical data. But it is a degrader, not an old-fashioned TKI.
Abstract of ASH presentation is posted. It has data as of May 30, 2023. However, "Updated enrollment, safety, PK, and response data will be presented at the meeting along with findings on the association between somatic mutations and TUS sensitivity as well as results for the TUS food-effect absorption study". I guess, most interesting is mutations and TUS sensitivity.
https://ash.confex.com/ash/2023/webprogram/Paper182296.html
I think, best option for them is to sell the company. Data looks good, they need to demonstrate durability and an offer will follow. With this low MC, a BO for around $100M looks very generous. Second option is to out-license Tusp for high upfront payment. But it will leave Aptose without pipeline.
So, anyone have any idea how they continue as a going concern in this market. I agree, TUSP looks promising but not promising enough for Big Pharma. Brutal market, company sold 20% of the company for $7 million, let that sink in. Where does financing come from? If it’s a reverse merger, I assume we will be diluted once again.
I'm still here and watching. The elephant in the room is financing.
Decaf, Thanks for the updates! Have you heard from Tartia at all?
Canaccord Genuity analyst John Newman has maintained their bullish stance on APTO stock, giving a Buy rating yesterday.
John Newman’s Buy rating for Aptose Biosciences is largely influenced by several crucial factors. To start with, the promising data from the APTIVATE Phase 1/2 trial for tuspetinib, both as a monotherapy and in combination with venetoclax, has been a major driver. The positive results of the trial in Acute Myeloid Leukemia (AML) patients who have failed prior venetoclax treatment are particularly noteworthy. Newman is also optimistic about the potential for further data updates regarding the tuspetinib and venetoclax combination, as well as additional response duration data expected in the first half of 2024.
In addition to the encouraging trial data, Newman also highlights the shift in focus of the drug’s application to patients who have failed venetoclax treatment, rather than just those with FLT3/TP53 mutations. The safety profile of the drug combination, despite elevated levels of febrile neutropenia and leucopenia, is also deemed manageable. Tuspetinib continues to show a clean safety profile, further boosting Newman’s confidence. Furthermore, Aptose’s expansion plans for tuspetinib into earlier lines of therapy in AML, as well as its planned extension into High-Risk Myelodysplastic Syndromes (HR-MDS) and Chronic Myelomonocytic Leukemia (CMML), are seen as potentially valuable additions to the franchise. Lastly, Aptose’s recent financial agreements also contribute to the positive outlook.
In another report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $23.00 price target.
Oppenheimer analyst Matthew Biegler maintained a Buy rating on Aptose Biosciences today and set a price target of $15.00. The company’s shares closed yesterday at $2.75.
It's great news.....but......will the company forge ahead with the 160 mg dose that works and actually work toward a Phase III? No word on Lux.
Negative reaction to the news could be explained by the data demonstrating that most of new responses are PRs, not CRs.
Decaf, would you be buying now? tia
They reported efficacy data on 31 patients. Most important, efficacy is not detiorating with with higher N.
Poster presentation has efficacy data on 15 Tusp/Ven treated patients. Rice said, expect 30. Will we see data on 30 patients tomorrow? Data looks good. Patients with Flt3 mutations have better outcome with the doublet.
Short-term optimistic, between now and ASH.
Decaf, are you optimistic, own any or buying any shares? tia
What news to expect in next 1.5 months:
1. Update at ESH with 30 patients, should be positive.
2. EC, we might hear about partnering talks/interest.
3. Initiation of MDS study, guess, neutral news.
4. Update at ASH with 45 patients, most important catalyst. Will have clarity on how good Tusp is. If really good, expect buyout or partnering shortly after.
I’m guessing the market will shrug off any positive news regarding TUSP. In my opinion, only some kind of M&A deal or partnership can save the company.
Analyst Joseph Pantginis of H.C. Wainwright reiterated a Buy rating on Aptose Biosciences (APTO – Research Report), with a price target of $23.00.
Joseph Pantginis has given his Buy rating due to a combination of factors that point towards a potentially significant shift in the fortunes of Aptose Biosciences’s stock (APTO). The key driver behind this optimistic outlook is the strengthening case for tuspetinib, an investigational drug being developed by the company. Pantginis believes that the company is on the cusp of a tipping point, given the emerging data and his expectations about the drug’s potential.
Pantginis also considers the upcoming data readouts from APTIVATE to be a critical factor in shaping his recommendation. He anticipates that these readouts, which will provide insights into the drug’s impacts based on mutation status, will contribute to a tipping point in APTO’s stock performance. Furthermore, Pantginis sees the potential of tuspetinib to resensitize patients who have not responded well to other treatments as a significant value proposition. In conclusion, Pantginis’s Buy rating is primarily driven by the promising prospects of tuspetinib and the expected positive impact on the company’s stock.
Obviously no interest here. They just gave away 20% of the ENTIRE company for $7 million. That means Lux is another flop. This is headed to a $15 million market cap. So pathetic.
Does anyone know when and where their October conference is? tia
Market cap of Aptose is less than $20M. I wonder why any larger biotech company don't buy Aptose for $40 or $60M. 100% or 200% premium looks attractive. And Tusp would be a nice addition to any hematologic oncology pipeline, especially for this steal price. Or is it that nobody see a value in Tusp?
From what Rice said at today's Cantor conference:
1. Already reported Tusp/Ven data with 15 patients. Will have data with around 30 and 45 patients at ESH and ASH, respectively. At ASH, will focus on durability.
2. Cash enough to the end of Q1 2024.
3. Lux was not even mentioned.
This Board consists of seasoned physicians and technical people with really good reputations. I would imagine they have their own personal stakes in this venture and know where the risks are....including the risks to their own reputations.
Wolverine, I feel your pain. I’m down a bundle too.
This will take a Miracle. If no partner steps up, bankruptcy will be a real option. There are no other alternatives at this point. They can’t raise any money, they just sold 20% of the company for $7 million. What a mess, I can see this management team filing bankruptcy and start the Ponzi scheme all over again. Unfortunately, I will lose a lot.
22 cents pre-reverse split. This phenomenon is not acute to APTO. It happens to any/all companies who effect a reverse split to try and retain the NASDAQ listing going forward but then do not have the improvements to the business model to support the elevated stock price.
Interesting from bio of Philippe Ledru. "At Merck, he also provided leadership on all licensing and M&A activities, including the Peloton Therapeutics and Arqule acquisitions in 2019".
I didn't hear anything new in what Rice said. According to slide 26, they won't start a registrational trial until 3Q24. They don't have money to run their business one more year. Dilution is not an option. I think, their last chance is to demonstrate something spectacular at ASH in December and then license Tusp or sell the company.
Any thoughts on the recent presentation? Decaf or Tartia? tia!
Followers
|
23
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
567
|
Created
|
10/19/05
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |